Literature DB >> 18077644

Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.

Dianne J Marais1, Debbie Constant, Bruce Allan, Henri Carrara, Margaret Hoffman, Samuel Shapiro, Chelsea Morroni, Anna-Lise Williamson.   

Abstract

There is a high incidence of cervical cancer in South African women. No large studies to assess human papillomavirus virus (HPV) infection or HPV type 16 (HPV-16) exposure have occurred in the region, a requirement for policy making with regards to HPV screening and the introduction of vaccines. Control women (n = 1,003) enrolled in a case control study of hormonal contraceptives and cervical cancer were tested for 27 cervical HPV types by reverse line blot analysis. The seroprevalence of HPV-16 immunoglobulin G (IgG) and IgA antibodies was assessed by a virus-like particle-based enzyme-linked immunoassay of 908 and 904 control women, respectively, and of 474 women with cervical cancer. The cervical HPV prevalence was 26.1%. The HPV-16 IgG seroprevalence was 44.4% and the HPV-16 IgA seroprevalence was 28.7% in control women, and these levels were significantly higher (61.8% and 52.7%, respectively) for women with cervical cancer (odds ratio [OR], 2.1 and 2.8, respectively). The cervical HPV prevalence showed an association with cervical disease, and the HPV-16 IgG prevalence decreased while the HPV-16 IgA prevalence increased with increasing age (P < 0.05). The prevalence of oncogenic HPV types (including HPV-16) decreased with age, whereas nononcogenic HPV types showed limited association with age. Multivariate analysis revealed cervical HPV infection to be associated with herpes simplex virus type 2 infection (OR, 1.7) and increasing years of education (OR, 1.9). HPV-16 IgG antibodies were inversely associated with current smoking status (OR, 0.6), and the presence of HPV-16 IgA antibodies was inversely associated with the use of alcohol (OR, 2.1) and inversely associated with the use of oral contraceptives (OR, 0.6). High levels of exposure to HPV, and particularly HPV-16, were evident in this population. The apparent increase of serum HPV-16 IgA with increasing age requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077644      PMCID: PMC2238115          DOI: 10.1128/JCM.01322-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.

Authors:  J J Carter; L A Koutsky; J P Hughes; S K Lee; J Kuypers; N Kiviat; D A Galloway
Journal:  J Infect Dis       Date:  2000-05-31       Impact factor: 5.226

2.  Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas.

Authors:  V M van Houten; P J Snijders; M W van den Brekel; J A Kummer; C J Meijer; B van Leeuwen; F Denkers; L E Smeele; G B Snow; R H Brakenhoff
Journal:  Int J Cancer       Date:  2001-07-15       Impact factor: 7.396

3.  Seroprevalence of human papillomavirus type 16 in pregnant women.

Authors:  M E Hagensee; J Slavinsky; C M Gaffga; J Suros; P Kissinger; D H Martin
Journal:  Obstet Gynecol       Date:  1999-11       Impact factor: 7.661

4.  Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica.

Authors:  Rolando Herrero; Philip E Castle; Mark Schiffman; M Concepción Bratti; Allan Hildesheim; Jorge Morales; Mario Alfaro; Mark E Sherman; Sholom Wacholder; Sabrina Chen; Ana C Rodriguez; Robert D Burk
Journal:  J Infect Dis       Date:  2005-05-02       Impact factor: 5.226

5.  Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.

Authors:  Yevgeniy Y Studentsov; Gloria Y F Ho; Morgan A Marks; Robert Bierman; Robert D Burk
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

6.  High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia.

Authors:  Patti Kay; Robbert Soeters; James Nevin; Lynette Denny; Catherine M C Dehaeck; Anna-Lise Williamson
Journal:  J Med Virol       Date:  2003-10       Impact factor: 2.327

7.  Characterization of IgA response among women with incident HPV 16 infection.

Authors:  Takashi Onda; Joseph J Carter; Laura A Koutsky; James P Hughes; Shu-Kuang Lee; Jane Kuypers; Nancy Kiviat; Denise A Galloway
Journal:  Virology       Date:  2003-07-20       Impact factor: 3.616

8.  Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa).

Authors:  Samuel Shapiro; Lynn Rosenberg; Margaret Hoffman; Judith P Kelly; Diane D Cooper; Henri Carrara; Lynnette E Denny; George du Toit; Bruce R Allan; Ilse A Stander; Anna-Lise Williamson
Journal:  Cancer Causes Control       Date:  2003-06       Impact factor: 2.506

9.  Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.

Authors:  Raphael P Viscidi; Linda Ahdieh-Grant; Barbara Clayman; Kelly Fox; Leslie S Massad; Susan Cu-Uvin; Keerti V Shah; Kathryn M Anastos; Kathleen E Squires; Ann Duerr; Denise J Jamieson; Robert D Burk; Robert S Klein; Howard Minkoff; Joel Palefsky; Howard Strickler; Paula Schuman; Eva Piessens; Paolo Miotti
Journal:  J Infect Dis       Date:  2003-01-06       Impact factor: 5.226

10.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.

Authors:  G M Clifford; J S Smith; M Plummer; N Muñoz; S Franceschi
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more
  13 in total

Review 1.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

2.  Viral infections associated with oral cancers and diseases in the context of HIV: a workshop report.

Authors:  D J Speicher; V Ramirez-Amador; D P Dittmer; J Webster-Cyriaque; M T Goodman; A-B Moscicki
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

3.  Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women.

Authors:  Jennifer S Smith; Adam K Lewkowitz; You-Lin Qiao; Jia Ji; Shangying Hu; Wen Chen; Rong Zhang; Kai Li Liaw; Mark Esser; Frank J Taddeo; Robert G Pretorius; Jerome L Belinson
Journal:  Int J Cancer       Date:  2012-01-27       Impact factor: 7.396

4.  Association of oncogenic and nononcogenic human papillomavirus with HIV incidence.

Authors:  Bertran Auvert; Pascale Lissouba; Ewalde Cutler; Kevin Zarca; Adrian Puren; Dirk Taljaard
Journal:  J Acquir Immune Defic Syndr       Date:  2010-01       Impact factor: 3.731

5.  Association of antibody to E2 protein of human papillomavirus and p16INK4A with progression of HPV-infected cervical lesions.

Authors:  Jureeporn Chuerduangphui; Chamsai Pientong; Piyawut Swangphon; Sanguanchoke Luanratanakorn; Ussanee Sangkomkamhang; Thumwadee Tungsiriwattana; Pilaiwan Kleebkaow; Ati Burassakarn; Tipaya Ekalaksananan
Journal:  Med Oncol       Date:  2018-05-09       Impact factor: 3.064

6.  High Burden of Human Papillomavirus (HPV) Infection among Young Women in KwaZulu-Natal, South Africa.

Authors:  Sumayyah Ebrahim; Xolani K Mndende; Ayesha B M Kharsany; Zizipho Z A Mbulawa; Vivek Naranbhai; Janet Frohlich; Lise Werner; Natasha Samsunder; Quarraisha Abdool Karim; Anna-Lise Williamson
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

7.  Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal study.

Authors:  Stuart Collins; Terry P Rollason; Lawrence S Young; Ciaran B J Woodman
Journal:  Eur J Cancer       Date:  2009-10-12       Impact factor: 9.162

8.  Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women.

Authors:  Papa Salif Sow; Deborah Watson-Jones; Nancy Kiviat; John Changalucha; Khardiata Diallo Mbaye; Joelle Brown; Kouro Bousso; Bazil Kavishe; Aura Andreasen; Macoumba Toure; Saidi Kapiga; Philippe Mayaud; Richard Hayes; Marie Lebacq; Marjan Herazeh; Florence Thomas; Dominique Descamps
Journal:  J Infect Dis       Date:  2012-12-13       Impact factor: 5.226

9.  Maternal transmission of human papillomavirus in retinoblastoma: A possible route of transfer.

Authors:  Anand Bhuvaneswari; V R Pallavi; R S Jayshree; Rekha V Kumar
Journal:  Indian J Med Paediatr Oncol       Date:  2012-10

10.  Transplacental transmission of Human Papillomavirus.

Authors:  Renato L Rombaldi; Eduardo P Serafini; Jovana Mandelli; Edineia Zimmermann; Kamille P Losquiavo
Journal:  Virol J       Date:  2008-09-25       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.